Q
Quince Therapeutics, Inc. (QNCX)
NMS – Real Time Price. Currency in USD
0.94
-0.03 (-3.34%)
At close: Jun 26, 2026, 4:00 PM EDT
0.96
+0.02 (1.63%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
0.94
-0.03 (-3.34%)
At close: Jun 26, 2026, 4:00 PM EDT
0.96
+0.02 (1.63%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Charles S. Ryan J.D., Ph.D. | President |
| Dr. Dirk Thye M.D. | CEO, Chief Medical Officer & Director |
| Mr. Brendan Hannah M.B.A. | Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-26 | 8-K | d168420d8k.htm |
| 2026-06-11 | 8-K | d124733d8k.htm |
| 2026-05-21 | 8-K | d139014d8k.htm |
| 2026-05-18 | 8-K/A | d135388d8ka.htm |
| 2026-05-18 | 8-K | d109149d8k.htm |
| 2026-05-11 | 10-Q | qncx-20260331.htm |
| 2026-04-28 | 8-K | d623526d8k.htm |
| 2026-04-27 | DEFA14A | qncx-20260424.htm |
| 2026-04-27 | DEF 14A | qncx-20260424.htm |
| 2026-04-27 | ARS | qncx-ars-fy2025.pdf |